SHARJAH-ART-FOUNDATION
7.3.2019 18:28:04 CET | Business Wire | Press release
Under the patronage of His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, the 14th edition of Sharjah Biennial (SB14) commenced on Thursday at the Sharjah Art Foundation (SAF) Art Spaces in Al Mureijah.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190307005593/en/
SB14, held this year under the title ‘Leaving the Echo Chamber’, will feature three distinct exhibitions; Zoe Butt’s exhibition Journey Beyond The Arrow; Omar Kholeif’s Making New Time and Claire Tancons’ Look for Me All Around You.
SB14 features over 80 established and emerging artists from around the globe, including over 60 new commissions, as well as many never-before-seen works that will displayed in various locations across the emirate of Sharjah, the Mureijah Square and the Arts Square, as well as in SAF’s studios in Al Hamriyah, in the East Coast city of Kalba and other spaces in Umm Al Quwain.
The Sharjah Art Foundation is also organizing the 12th edition of the March Meeting 2019, from 9 -11 March, 2019 at the Sharjah Institute of Theatrical Arts in Al Mureijah, which will include panel discussions, performances, films and artistic productions, in line with the themes of the three exhibitions at SB14.
SB14 will also feature independent film screenings for film lovers in the UAE; as well as educational programs, aligned with this year’s theme ‘Leaving the Echo Chamber’.
Programs intended for adults and children include workshops on photography, drawing, writing and theatrical performance. Other workshops for ‘People of determination’ provide a variety of topics on photography skills, puppetry, drawing, musical instruments and Islamic art; while the schools and youth centers’ program offers a set of workshops and field trips on topics such as abstract art, architecture and storytelling.
SB14 is made possible through the generous support of Van Cleef & Arples (Gold Sponsor) and Crescent Petroleum (Silver Sponsor). In-kind support is offered by Sharjah Municipality, Sharjah Roads and Transport Authority; Sharjah Electricity and Water Authority; Bee'ah, the Dubai Economic Department; the Institut Français in the UAE and the Institut Français in France.
The Sharjah Biennial is the most important cultural event in the Arab world and, since its inception in 1993, has been instrumental in supporting the arts landscape in the UAE and the region.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005593/en/
Contact:
Hussain Al Mulla , Media Relations Executive +971563980067 Hussain.AlMulla@SGMB.ae
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom